Status:
COMPLETED
Identifying Unique Pathogenic Macrophages in Systemic Sclerosis-ILD
Lead Sponsor:
Northwestern University
Conditions:
Fibrosis Lung
Systemic Sclerosis
Eligibility:
All Genders
18+ years
Brief Summary
Alveolar macrophages isolated from bronchoalveolar lavage (BAL) fluid from systemic sclerosis (SSc) patients with clinically significant lung fibrosis will be studied at baseline and at 6 months after...
Detailed Description
Using cutting-edge single cell RNA-Seq technology, we will identify in the BAL fluid of subjects of SSc-ILD emerging pathogenic cell populations in the lung that were previously unrecognized using sta...
Eligibility Criteria
Inclusion
- meet 2013 ACR criteria for diagnosis of SSc
- have radiographic evidence for ILD and a forced vital capacity \<70% on PFT
- have not taken immune suppression in the last 2 months OR have taken a stable dose of mycophenolate mofetil, rituximab, or prednisone less than or equal to 10 mg for at least 6 months
Exclusion
- diagnosis of an overlap syndrome, such as lupus or rheumatoid arthritis
- unable to provide informed consent in English
- currently pregnant or nursing
- current smoker or former smoker (greater than 10 pack years)
- leukopenia
- anemia
- comorbidities of uncontrolled congestive heart failure, cancer not in remission, HIV, or chronic liver disease
- known or suspected infection in the past 3 months
- BMI greater than or equal to 30 kg/m2
Key Trial Info
Start Date :
June 28 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 8 2024
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT03438032
Start Date
June 28 2018
End Date
March 8 2024
Last Update
November 14 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwestern University
Chicago, Illinois, United States, 60611